EA020130B9 - Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата - Google Patents
Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгатаInfo
- Publication number
- EA020130B9 EA020130B9 EA200800642A EA200800642A EA020130B9 EA 020130 B9 EA020130 B9 EA 020130B9 EA 200800642 A EA200800642 A EA 200800642A EA 200800642 A EA200800642 A EA 200800642A EA 020130 B9 EA020130 B9 EA 020130B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugate
- antigen
- methods
- same
- specific antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение направлено на моноклональное антитело и его эпитопсвязывающие фрагменты, которые распознают и связываются с гликотопом СА6, в частности на гуманизованные или поверхностно-перестроенные варианты моноклонального антитела DS6 мыши против СА6 и его эпитопсвязывающие фрагменты. Изобретение также относится к цитотоксическому конъюгату, содержащему указанные антитела, и к композициям, содержащим конъюгат, которые могут использоваться при ингибировании роста клеток и лечении раковых заболеваний.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/030115 WO2007024222A1 (en) | 2005-08-22 | 2005-08-22 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Publications (3)
Publication Number | Publication Date |
---|---|
EA200800642A1 EA200800642A1 (ru) | 2008-08-29 |
EA020130B1 EA020130B1 (ru) | 2014-08-29 |
EA020130B9 true EA020130B9 (ru) | 2014-10-30 |
Family
ID=37771883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200800642A EA020130B9 (ru) | 2005-08-22 | 2005-08-22 | Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1917034A4 (ru) |
JP (1) | JP2009504193A (ru) |
CN (1) | CN101242855A (ru) |
AU (1) | AU2005335743A1 (ru) |
BR (1) | BRPI0520509A2 (ru) |
CA (1) | CA2615761A1 (ru) |
EA (1) | EA020130B9 (ru) |
EC (1) | ECSP088241A (ru) |
HK (1) | HK1211965A1 (ru) |
IL (2) | IL189628A0 (ru) |
MX (1) | MX2008002607A (ru) |
NO (1) | NO20080893L (ru) |
WO (1) | WO2007024222A1 (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
RU2015137856A (ru) * | 2013-02-05 | 2017-03-13 | Санофи | Иммунологическое визуализирующее средство для использования при терапии конъюгатом антитело-лекарственное средство |
CA2900154A1 (en) * | 2013-02-05 | 2014-08-14 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9844607B2 (en) | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
JP2016525560A (ja) * | 2013-08-02 | 2016-08-25 | サノフイ | 固形腫瘍を処置するための抗−Muc1メイタンシノイドイムノコンジュゲート抗体の使用 |
WO2016036861A1 (en) | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
TWI697493B (zh) | 2014-09-03 | 2020-07-01 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
RS65120B1 (sr) | 2015-11-25 | 2024-02-29 | Immunogen Inc | Farmaceutske formulacije i postupci za njihovu upotrebu |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
TW201839001A (zh) | 2017-04-20 | 2018-11-01 | 美商伊繆諾金公司 | 細胞毒性苯并二氮平衍生物及其綴合物 |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2019133652A1 (en) | 2017-12-28 | 2019-07-04 | Immunogen, Inc. | Benzodiazepine derivatives |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
CN102940889A (zh) * | 2003-05-14 | 2013-02-27 | 伊缪诺金公司 | 药物缀合物组合物 |
WO2005009369A2 (en) * | 2003-07-21 | 2005-02-03 | Immunogen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
-
2005
- 2005-08-22 CA CA002615761A patent/CA2615761A1/en not_active Abandoned
- 2005-08-22 JP JP2008527882A patent/JP2009504193A/ja not_active Withdrawn
- 2005-08-22 EP EP05788869A patent/EP1917034A4/en not_active Withdrawn
- 2005-08-22 WO PCT/US2005/030115 patent/WO2007024222A1/en active Application Filing
- 2005-08-22 BR BRPI0520509-3A patent/BRPI0520509A2/pt not_active Application Discontinuation
- 2005-08-22 MX MX2008002607A patent/MX2008002607A/es not_active Application Discontinuation
- 2005-08-22 EA EA200800642A patent/EA020130B9/ru not_active IP Right Cessation
- 2005-08-22 AU AU2005335743A patent/AU2005335743A1/en not_active Abandoned
- 2005-08-22 CN CNA200580051368XA patent/CN101242855A/zh active Pending
-
2008
- 2008-02-20 NO NO20080893A patent/NO20080893L/no not_active Application Discontinuation
- 2008-02-20 IL IL189628A patent/IL189628A0/en unknown
- 2008-03-05 EC EC2008008241A patent/ECSP088241A/es unknown
-
2015
- 2015-05-13 IL IL238798A patent/IL238798A0/en unknown
- 2015-12-31 HK HK15112923.0A patent/HK1211965A1/xx unknown
Non-Patent Citations (2)
Title |
---|
PAYNE et al. (a) (PG PUB 20050123549 A1) 9 June 2005 (09.06 2005), Abstract and Summary of invetion in particular * |
PAYNE et al. (b) (WO 2005/009369) 3 February 2005 (03.02.2005), Abstract and Summary of invetion in particular * |
Also Published As
Publication number | Publication date |
---|---|
CN101242855A (zh) | 2008-08-13 |
EP1917034A1 (en) | 2008-05-07 |
JP2009504193A (ja) | 2009-02-05 |
ECSP088241A (es) | 2008-04-28 |
EA200800642A1 (ru) | 2008-08-29 |
HK1211965A1 (en) | 2016-06-03 |
EA020130B1 (ru) | 2014-08-29 |
IL238798A0 (en) | 2015-06-30 |
AU2005335743A1 (en) | 2007-03-01 |
WO2007024222A1 (en) | 2007-03-01 |
MX2008002607A (es) | 2008-03-19 |
IL189628A0 (en) | 2008-06-05 |
EP1917034A4 (en) | 2009-04-29 |
CA2615761A1 (en) | 2007-03-01 |
BRPI0520509A2 (pt) | 2009-05-12 |
NO20080893L (no) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA020130B9 (ru) | Специфичное к антигену са6 антитело, содержащий его цитотоксический конъюгат и способы применения конъюгата | |
HK1098160A1 (en) | A ca6 antigen-specific cytotoxic conjugate and methods of using the same ca6 | |
MX2007009377A (es) | Variantes de anticuerpo y usos de las mismas. | |
EP1996716A4 (en) | MODIFIED ANTIBODIES AGAINST THE ANTIGEN OF PROSTATIC STEM CELLS FOR TARGETING CANCER | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
MX2009003838A (es) | Anticuerpos anti-cd20 y metodos de uso. | |
WO2006099141A3 (en) | Anti-mesothelin antibodies | |
NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
TN2009000058A1 (en) | Novel anti-cd38 antibodies for the treatment of cancer | |
NZ572756A (en) | Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody | |
IL187594A0 (en) | Humanized anti-cd40 antibodies and their methods of use | |
MY157757A (en) | Antagonist antibody against epha2 for the treatment of cancer | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
SG151284A1 (en) | Antibodies against ccr5 and uses thereof | |
WO2010113117A3 (en) | Preparation of isolated agonist anti-edar monoclonal antibodies | |
MX2018005541A (es) | Moleculas de union especificas para transportador 2 con preferencia a alanina, serina y cistenia (asct2) y usos de las mismas. | |
NZ593171A (en) | Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): MD |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |